Sitavig registered in seven European countries

BioAlliance Pharma's Sitavig (aciclovir Lauriad) has been approved for the treatment of recurrent labial herpes in the following European countries: Sweden, the UK, Spain, Italy, Denmark, Finland and Norway.

The decentralised procedure, with Sweden as Reference Member State, ended with a positive opinion for these first seven countries. Each country will now issue a national marketing authorisation in the coming weeks.

BioAlliance Pharma plans to pursue the submission of the registration dossier in other European countries as soon as the first quarter of 2013.


Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.